Their decision to eliminate coverage based on safety and efficacy is fascinating, because I don't know that there's any new safety or efficacy data that's happened in the interim that would warrant that decision
Interestingly, glutathiones role in skin lightening is not its only claim to fame
These older GLP-1 drugs remain in use but have been largely overtaken by semaglutide and tirzepatide in new prescriptions
J Neuroinflammation 16(1):217 Jiang L, Zhang Y, Jing F, Long T, Qin G, Zhang D, Chen L, Zhou J (2021) P2 7R-mediated autophagic impairment contributes to central sensitization in a chronic migraine model with recurrent nitroglycerin stimulation in mice
Others show promise but still rely heavily on animal studies, small trials, and aggressive marketing